Antisense oligonucleotide-based therapeutics

Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, Fourth Edition

Volumn , Issue , 2015, Pages 467-492

  Bennett, C Frank ^a   Swayze, Eric ^a   Henry, Scott ^a,a   Geary, Richard ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85009118442     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b18002     Document Type: Chapter

References (272)

1. Watson, J. and Crick, F. (1953) Molecular structure of nucleic acids: A structure for deoxyribose nucleic acid. Nature 171, 737.
2. McKay, R. A., Miraglia, L. J., Cummins, L. L., Owens, S. R., Sasmor, H., and Dean, N. M. (1999) Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression. J. Biol. Chem. 274, 1715-1722.
3. Lanz, R. B., McKenna, N. J., Onate, S. A., Albrecht, U., Wong, J., Tsai, S. Y., Tsai, M. J., and O’Malley, B. W. (1999) A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell 97, 17-27.
4. Esau, C., Kang, X., Peralta, E., Hanson, E., Marcusson, E. G., Ravichandran, L. V., Sun, Y. et al. (2004) Micro-RNA-143 regulates adipocyte differentiation. J. Biol. Chem. 279, 52361-52365.
5. Esau, C., Davis, S., Murray, S. F., Yu, X. X., Pandey, S. K., Pear, M., Watts, L. et al. (2006) miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 3, 87-98.
6. Krutzfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., and Stoffel, M. (2005) Silencing of microRNAs in vivo with “antagomirs”. Nature 438, 685-689.
7. Prasanth, K. V., Prasanth, S. G., Xuan, Z., Hearn, S., Freier, S. M., Bennett, C. F., Zhang, M. Q., and Spector, D. L. (2005) Regulating gene expression through RNA nuclear retention. Cell 123, 249-263.
8. Hung, G., Xiao, X., Peralta, R., Bhattacharjee, G., Murray, S., Norris, D., Guo, S., and Monia, B. P. (2013) Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals. Nucleic Acid Ther.23, 369-378.
9. Gutschner, T., Hammerle, M., Eissmann, M., Hsu, J., Kim, Y., Hung, G., Revenko, A. et al. (2013) The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 73, 1180-1189.
10. Chiang, M. Y., Chan, H., Zounes, M. A., Freier, S. M., Lima, W. F., and Bennett, C. F. (1991) Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J. Biol. Chem. 266, 18162-18171.
11. Bennett, C. F., Condon, T. P., Grimm, S., Chan, H., and Chiang, M. Y. (1994) Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. J. Immunol. 152, 3530-3540.
12. Dean, N. M., McKay, R., Condon, T. P., and Bennett, C. F. (1994) Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J. Biol. Chem. 269, 16416-16424.
13. Monia, B. P., Johnston, J. F., Geiger, T., Muller, M., and Fabbro, D. (1996) Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med. 2, 668-675.
14. Freier, S. M. and Watt, A. T. (2008) Basic principles of antisense drug discovery. in Antisense Drug Technology. Principles, Strategies, and Applications (Crooke, S. T. ed.), Taylor & Francis, Boca Raton, FL. pp. 117-142.
15. Monia, B. P., Lesnik, E. A., Gonzalez, C., Lima, W. F., McGee, D., Guinosso, C. J., Kawasaki, A. M., Cook, P. D., and Freier, S. M. (1993) Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268, 14514-14522.
16. Lima, W. F., Wu, H., and Crooke, S. T. (2001) Human RNases H. Methods Enzymol. 341, 430-440.
17. Wu, H., Lima, W. F., Zhang, H., Fan, A., Sun, H., and Crooke, S. T. (2004) Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J. Biol. Chem. 279, 17181-17189.
18. Lima, W. F., Rose, J. B., Nichols, J. G., Wu, W., Migawa, M. T., Wyrzykiewicz, T. K., and Crooke, S. T. (2007) Human RNase H1 discriminates between subtle variations in the structure of the heteroduplex substrate. Mol. Pharmacol. 71, 6598-6610.
19. Lima, W. F., Nichols, J. G., Wu, H., Prakash, T. P., Migawa, M. T., Wyrzykiewicz, T. K., Bhat, B., and Crooke, S. T. (2004) Structural requirements at the catalytic site of the heteroduplex substrate for human RNase H1 catalysis. J. Biol. Chem. 279, 36317-36326.
20. Cerritelli, S. M. and Crouch, R. J. (2009) Ribonucelase H: The enzymes in eukaryotes. FEBS J. 276, 1494-1505.
21. Yu, X. X., Pandey, S. K., Booten, S. L., Murray, S. F., Monia, B. P., and Bhanot, S. (2008) Reduced adiposity and improved insulin sensitivity in obese mice with antisense suppression of 4E-BP2 expression. Am. J. Phys. Endocrin. Metab. 294, E530-E539.
22. Yamaguchi, K., Yang, L., McCall, S., Huang, J., Yu, X. X., Pandey, S. K., Bhanot, S., Monia, B. P., Li, Y. X., and Diehl, A. M. (2008) Diacylglycerol acyltranferase 1 antisense oligonucleotides reduce hepatic fibrosis in mice with nonalcoholic steatohepatitis. Hepatology 47, 625-635.
23. Wheeler, T. M., Leger, A. J., Pandey, S. K., MacLeod, A. R., Nakamori, M., Cheng, S. H., Wentworth, B. M., Bennett, C. F., and Thornton, C. A. (2012) Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488, 111-115.
24. Kordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. M., Pytel, K. A., Artates, J. W. et al. (2012) Sustained therapeutic reversal of Huntington’s disease by transient repression of huntingtin synthesis. Neuron 74, 1031-1044.
25. Graham, M. J., Lee, R. G., Bell, T. A., 3rd, Fu, W., Mullick, A. E., Alexander, V. J., Singleton, W. et al. (2013) Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ. Res. 112, 1479-1490.
26. Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., and Mello, C. C. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811.
27. Elbashir, S. M., Lendeckel, W., and Tuschl, T. (2001) RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 15, 188-200.
28. Zamore, P. D. (2002) Ancient pathways programmed by small RNAs. Science 296, 1265-1269.
29. Zamore, P. D., Tuschl, T., Sharp, P. A., and Bartel, D. P. (2000) RNAi: Double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101, 25-33.
30. Ghilidiyal, M. and Zamore, P. D. (2009) Small RNAs: An expanding universe. Nat. Rev. Genet. 10, 94-108.
31. Carthew, R. W. and Sontheimer, E. J. (2009) Origins and mechanisms of miRNAs and siRNAs. Cell 136, 642-655.
32. Sontheimer, E. J. (2005) Assembly and function of RNA silencing complexes. Nat. Rev. Mol. Cell Biol. 6, 127-138.
33. Song, J.-J., Smith, S. K., Hannon, G. J., and Joshua-Tor, L. (2004) Crystal structure of argonaute and its implications for RISC slicer activity. Science 305, 1434-1437.
34. Wang, Y., Juranek, S., Li, H., Sheng, G., Tuschl, T., and Patel, D. J. (2008) Structure of an argonaute silencing complex with seed-containing guide DNA and target RNA duplex. Nature 456, 921-926.
35. Yu, D., Pendergraff, H., Liu, J., Kordasiewicz, H. B., Cleveland, D. W., Swayze, E. E., Lima, W. F., Crooke, S. T., Prakash, T. P., and Corey, D. R. (2012) Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell 150, 895-908.
36. Lima, W. F., Prakash, T. P., Murray, H. M., Kinberger, G. A., Li, W., Chappell, A. E., Li, C. S. et al. (2012) Single-stranded siRNAs activate RNAi in animals. Cell 150, 883-894.
37. Torrence, P. F., Maitra, R. K., Lesiak, K., Khamnei, S., Zhou, A., and Silverman, R. H. (1993) Targeting RNA for degradation with a (2'-5') oligoadenylate-antisense chimera. Proc. Natl. Acad. Sci. USA 90, 1300-1304.
38. Maran, A., Maitra, R. K., Kumar, A., Dong, B., Xiao, W., Li, G., Williams, B. R. G., Torrence, P. F., and Silverman, R. H. (1994) Blockage of NF-kB signaling by selective ablation of an mRNA target by 2-5A antisense chimeras. Science 265, 789-792.
39. Leaman, D. W., Longano, F. J., Okicki, J. R., Soike, K. F., Torrence, P. F., Silverman, R. H., and Cramer, H. (2002) Targeted therapy of respiratory syncytial virus in African green monkeys by intranasally administered 2-5A antisense. Virology 292, 70-77.
40. Helene, C. and Toulm, J.-J. (1990) Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim. Biophys. Acta Gene Struct. Expr. 1049, 99-125.
41. Zamecnik, P. C. and Stephenson, M. L. (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA 75, 289-294.
42. Baker, B. F., Lot, S. S., Condon, T. P., Cheng-Flournoy, S., Lesnik, E. A., Sasmor, H. M., and Bennett, C. F. (1997) 2'-O-(2-methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J. Biol. Chem. 272, 11994-12000.
43. Chin D. J., Green, G. A., Zon, G., Szoka, F. C., Jr.., and Straubinger, R. M. (1990) Rapid nuclear accumulation of injected oligodeoxyribonucleotides. New Biol. 2, 1091-1100.
44. Leonetti, J. P., Mechti, N., Degols, G., Gagnor, C., and Lebleu, B. (1991) Intracellular distribution of microinjected antisense oligonucleotides. Proc. Natl. Acad. Sci. USA 88, 2702-2706.
45. Bennett, C. F., Chiang, M. Y., Chan, H., Shoemaker, J. E. E., and Mirabelli, C. K. (1992) Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 41, 1023-1033.
46. Lorenz, P., Baker, B. F., Bennett, C. F., and Spector, D. L. (1998) Phosphorothioate antisense oligonucleotides induce the formation of nuclear bodies. Mol. Biol. Cell 9, 1007-1023.
47. Dominski, Z. and Kole, R. (1994) Identification and characterization by antisense oligonucleotides of exon and intron sequences required for splicing. Mol. Cell. Biol. 14, 7445-7454.
48. Dominski, Z. and Kole, R. (1993) Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA 90, 8673-8677.
49. Sierakowska, H., Sambade, M. J., Agrawal, S., and Kole, R. (1996) Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA 93, 12840-12844.
50. Friedman, K. J., Kole, J., Cohn, J. A., Knowles, M. R., Silverman, L. M., and Kole, R. (1999) Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides. J. Biol. Chem. 274, 36193-36199.
51. Sazani, P., Kang, S. H., Maier, M. A., Wei, C., Dillman, J., Summerton, J., Manoharan, M., and Kole, R. (2001) Nuclear antisense effects of neutral anionic and cationic oligonucleotide analogs. Nucleic Acids Res. 29, 3965-3974.
52. Taylor, J., Zhang, Q., Wyatt, J., and Dean, N. (1999) Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat. Biotechnol. 17, 1097-1100.
53. Karras, J. G., Maier, M. A., Lu, T., Watt, A., and Manoharan, M. (2001) Peptide nucleic acids are potent modulators of endogenous pre-mRNA splicing of the murine interleukin-5 receptor-a chain. Biochemistry 40, 7853-7859.
54. Sazani, P., Gemignani, F., Kang, S. H., Maier, M. A., Manoharan, M., Persmark, M., Bortner, D., and Kole, R. (2002) Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat. Biotechnol. 20, 1228-1233.
55. Hua, Y., Vickers, T. A., Baker, B. F., Bennett, C. F., and Krainer, A. R. (2007) Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol. 5, e73.
56. Vickers, T. A., Zhang, H., Graham, M. J., Lemonidis, K. M., Zhao, C., and Dean, N. M. (2006) Modification of MyD88 mRNA splicing and inhibition of IL-lbeta signaling in cell culture and in mice with a 2'-O-methoxyethyl-modified oligonucleotide. J. Immunol. 176, 3652-3661.
57. Sahashi, K., Hua, Y., Ling, K. K., Hung, G., Rigo, F., Horev, G., Katsuno, M., Sobue, G., Ko, C. P., Bennett, C. F., and Krainer, A. R. (2012) TSUNAMI: An antisense method to phenocopy splicing-associated diseases in animals. Genes Dev. 26, 1874-1884.
58. Hua, Y., Sahashi, K., Rigo, F., Hung, G., Horev, G., Bennett, C. F., and Krainer, A. R. (2011) Peripheral SMN restoration is essential for long-term rescue of a severe SMA mouse model. Nature 478, 123-126.
59. Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Abbs, S. et al. (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study. Lancet 378, 595-605.
60. Jearawiriyapaisarn, N., Moulton, H. M., Buckley, B., Roberts, J., Sazani, P., Fucharoen, S., Iversen, P. L., and Kole, R. (2008) Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol. Ther 16, 1624-1629.
61. van Deutekom, J. C., Janson, A. A., Ginjaar, I. B., Frankhuizen, W. S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J. T. et al. (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N. Engl. J. Med. 357, 2677-2686.
62. Roberts, J., Palma, E., Sazani, P., Orum, H., and Kole, R. (2006) Efficient and persistent splice switching by systemi-cally delivered LNA oligonucleotides in mice. Mol. Ther. 14, 471-475.
63. Kole, R., Krainer, A. R., and Altman, S. (2012) RNA therapeutics: Beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug Discov. 11, 125-140.
64. Lentz, J. J., Jodelka, F. M., Hinrich, A. J., McCaffrey, K. E., Farris, H. E., Spalitta, M. J., Bazan, N. G., Duelli, D. M., Rigo, F., and Hastings, M. L. (2013) Rescue of hearing and vestibular function by antisense oligonucleotides in a mouse model of human deafness. Nat. Med. 19, 345-350.
65. Bauman, J., Jearawiriyapaisarn, N., and Kole, R. (2009) Therapeutic potential of splice-switching oligonucleotides. Oligonucleotides 19, 1-14.
66. Zammarchi, F., de Stanchina, E., Bournazou, E., Supakorndej, T., Martires, K., Riedel, E., Corben, A. D., Bromberg, J. F., and Cartegni, L. (2011) Antitumorigenic potential of STAT3 alternative splicing modulation. Proc. Natl. Acad. Sci. USA 108, 17779-17784.
67. Vickers, T. A., Wyatt, J. R., Burckin, T., Bennett, C. F., and Freier, S. M. (2001) Fully modified 2'-MOE oligonucleotides redirect polyadenylation. Nucleic Acids Res. 29, 1293-1299.
68. Lanford, R. E., Hildebrandt-Eriksen, E. S., Petri, A., Persson, R., Lindow, M., Munk, M. E., Kauppinen, S., and Orum, H. (2010) Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198-201.
69. Froehler, B. C., Jones, R. J., Cao, X., and Terhorst, T. J. (1993) Oligonucleotides derived from 5-(-propynyl)-2'-O-allyl-uridine and 5-(1-propynyl)-2'-O-allyl-cytidine: Synthesis and RNA duplex formation. Tetrahedron Lett. 34, 1003-1006.
70. Gutierrez, A. J., Terhorst, T. J., Matteucci, M. D., and Froehler, B. C. (1994) 5-Heteroaryl-2'-deoxyuridine analogs. Synthesis and incorporation into high-affinity oligonucleotides. J. Am. Chem. Soc. 116, 5540-5544.
71. Guttierrez, A. J. and Froehler, B. C. (1996) RNA duplex formation of oligodeoxynucleotides containing C-5 alkyne and C-5 thiazole substituted deoxyuridine analogs. Tetrahedron Lett. 37, 3959-3962.
72. Lin, K.Y., Pudlo, J. S., Jones, R. J., Bischofberger, N., Matteucci, M. D., and Froehler, B. C. (1994) Oligodeoxynucleotides containing 5(1-propynyl)-2'-deoxyuridine formacetal and thioformacetal dimer synthons. Bioorg. Med. Chem. Lett. 4, 1061-1064.
73. Seela, F. and Thomas, H. (1995) Duplex stabilization of DNA: Oligodeoxyribonucleotides containing 7-substituted 7-deazaadenines. Helv. Chim. Acta 78, 94-108.
74. Seela, F., Zulauf, M., Rosemeyer, H., and Reuter, H. (1996) The DNA-stabilizing nucleoside 7-iodo-2'-deoxytubercidin: Its structure in the solid state and in solution. J. Chem. Soc., Perkin Trans. 2, 2373-2376.
75. Balow, G., Mohan, V., Lesnik, E. A., Johnston, J. F., Monia, B. P., and Acevedo, O. L. (1998) Biophysical and antisense properties of oligodeoxynucleotides containing 7-propynyl-, 7-iodo- and 7-cyano-7deaza-2-amino-2'-deoxyadenosines. Nucleic Acids Res. 26, 3350-3357.
76. Flanagan, W. M., Wolf, J. J., Grant, D., Lin, K. Y., and Matteucci, M. D. (1999) Cellular penetration and antisense activity by a phenoxazine-substituted heptanucleotide. Nat. Biotechnol. 17, 48-52.
77. Lin, K.-Y., Jones, R. J., and Matteucci, M. (1995) Tricyclic-2'-deoxycytidine analogs: Synthesis and incorporation into oligodeoxynucleotides which have enhanced binding to complementary RNA. J. Am. Chem. Soc. 117, 3873-3874.
78. Lin, K. Y. and Matteucci, M. D. (1998). J. Am. Chem. Soc. 120, 8531-8532.
79. Flanagan, W. M., Wolf, J. J., Olson, P., Grant, D., Lin, K. Y., Wagner, R. W., and Matteucci, M. D. (1999) A cytosine analog that confers enhanced potency to antisense oligonucleotides. Proc. Natl. Acad. Sci. USA 96, 3513-3518.
80. Shen, L., Siwkowski, A., Wancewicz, E. V., Lesnik, E. A., Butler, M., Witchell, D., Vasquez, G. et al. (2003) Evaluation of C-5 propynyl pyrimidine-containing oligonucleotides in vitro and in vivo. Antisense Nucleic Acid Drug Dev. 13, 129-142.
81. Ramasamy, K. S., Zounes, M., Gonzalez, C., Freier, S. M., Lesnik, E. A., Cummins, L. L., Griffey, R. H., Monia, B. P., and Cook, P. D. (1994) Remarkable enhancement of binding affinity of heterocycle-modified DNA to DNA and RNA. Synthesis, characterization and biophysical evaluation of N2-imidazolylpropylguanine and N2-imidazolylpropyl-2-aminoadenine modified oligonucleotides. Tetrahedron Lett. 35, 215-218.
82. Manoharan, M., Ramasamy, K. S., Mohan, V., and Cook, P. D. (1996) Oligonucleotides bearing cationic N2-(3-aminopropyl) deoxyguanosine. Synthesis, enhanced binding properties and conjugation chemistry. Tetrahedron Lett. 37, 7675-7678.
83. Cook, P. D. (1998) Antisense medicinal chemistry. in Antisense Research and Application (Crooke, S. T. ed.), Springer-Verlag, Berlin, Germany. pp. 51-101.
84. Egli, M., Usman, N., and Rich, A. (1993) Conformational influence of the ribose 2'-hydroxyl group: Crystal structures of DNA-RNA chimeric duplexes. Biochemistry 32, 3221-3237.
85. Tereshko, v., Portmann, S., Tay, E. C., Martin, P., Natt, F., Altmann, K.-H., and Egli, M. (1998) Correlating structure and stability of DNA duplexes with incorporated 2'-O-modified RNA analogues. Biochemistry 37, 10626-10634.
86. Teplova, M., Minasov, G., Tereshko, V., Inamati, G. B., Cook, P. D., Manoharan, M., and Egli, M. (1999) Crystal structure and improved antisense properties of 2'-O-(2-methoxyethyl)-RNA. Nat. Struct. Biol. 6, 535-539.
87. Kastelein, J. J. P., Wedel, M. K., Baker, B. F., Su, J., Bradley, J. A., Yu, R. Z., Chuang, E., Graham, M. J., and Crooke, R. M. (2006) Potent reduction of Apolipoprotein B and LDL cholesterol by an antisense inhibitor of Apolipoprotein B. Circulation 114, 1729-1735.
88. Chi, K. M., Eisenhauer, E., Fazli, L., Jones, E. C., Goldenberg, S. L., Powers, J., and Gleave, M. E. (2005) A Phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense to clusterin, in patients with localized prostate cancer prior to radical prostatectomy. J. Natl. Cancer Inst. 97, 1287-1296.
89. Akdim, F., Tribble, D. L., Flaim, J. D., Yu, R., Su, J., Geary, R. S., Baker, B. F., Fuhr, R., Wedel, M. K., and Kastelein, J. J. (2011) Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J. 32, 2650-2659.
90. Santos, R. D., Duell, P. B., East, C., Guyton, J. R., Moriarty, P. M., Chin W., and Mittleman, R. S. (2013) Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur. Heart J. in press.
91. Hair, P., Cameron, F., and McKeage, K. (2013) Mipomersen sodium: First global approval. Drugs 73, 487-493.
92. Saad, F., Hotte, S., North, S., Eigl, B., Chi, K., Czaykowski, P., Wood, L. et al. and Canadian Uro-Oncology Group. (2011) Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin. Cancer Res. 17, 5765-5773.
93. Baylot, V., Andrieu, C., Katsogiannou, M., Taieb, D., Garcia, S., Giusiano, S., Acunzo, J., Iovanna, J., Gleave, M., Garrido, C., and Rocchi, P. (2011) OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer. Cell Death Dis. 2, e221.
94. Griffey, R. H., Monia, B. P., Cummins, L. L., Freier, S., Greig, M. J., Guinosso, C. J., Lesnik, E. et al. (1996) 2'-O-aminopropyl ribonucleotides: A zwitterionic modification that enhances the exonuclease resistance and biological activity of antisense oligonucleotides. J. Med. Chem.39, 5100-5109.
95. Prakash, T. P., Kawasaki, A. M., Vasquez, G., Fraser, A. S., Casper, M. D., Cook, P. D., and Manoharan, M. (1999) 2'-DMAOE RNA: Emerging oligonucleotides with promising antisense properties. Nucleosides Nucleotides 18, 1381-1382.
96. Prakash, T. P., Kawasaki, A. M., Fraser, A. S., Vasquez, G., and Manoharan, M. (2002) Synthesis of 2'-O-[2-[(N, N-dimethylamino)oxy]ethyl] modified nucleosides and oligonucleotides. J. Org. Chem. 67, 357-369.
97. Prakash, T. P., Siwkowski, A., Allerson, C. R., Migawa, M. T., Lee, S., Gaus, H. J., Black, C., Seth, P. P., Swayze, E. E., and Bhat, B. (2010) Antisense oligonucleotides containing conformationally constrained 2',4'-(N-methoxy)aminomethylene and 2',4'-aminooxymethylene and 2'-O,4'-C-aminomethylene bridged nucleoside analogues show improved potency in animal models. J. Med. Chem. 53, 1636-1650.
98. Koshkin, A. A., Nielsen, P., Meldgaard, M., Rajwanshi, V. K., Singh, S. K., and Wengel, J. (1998) LNA (locked nucleic acid): An RNA mimic forming exceedingly stable LNA:LNA duplexes. J. Am. Chem. Soc. 120, 13252-13253.
99. Singh, S. K., Nielsen, P., Koshkin, A. A., and Wengel, J. (1998) LNA (locked nucleic acids): Synthesis and high-affinity nucleic acid recognition. Chem. Commun. 455-456.
100. Seth, P. P., Siwkowski, A., Allerson, C. R., Vasquez, G., Lee, S., Prakash, T. P., Wancewicz, E. V., Witchell, D., and Swayze, E. E. (2009) Short antisense oligonucleotides with novel 2'-4' conformationally restricted nucleoside analogues show improved potency without increased toxicity in animals. J. Med. Chem. 52, 10-13.
101. Seth, P. P., Allerson, C. R., Ostergaard, M. E., and Swayze, E. E. (2012) Structural requirements for hybridization at the 5'-position are different in alpha-l-LNA as compared to beta-D-LNA. Bioorg. Med. Chem. Lett. 22, 296-299.
102. Seth, P. P. S., A., Allerson, C. R., Vasquez, G., Lee, S. H., Proakash, T. P., Wancewicz, E. V., Witchell, D., and Swayze, E. E. (2009) Short antisense oligonucleotides with novel 2'-4' conformational restricted nucleoside analogues show improved potency without incremental toxicity in animals. J. Med. Chem. 52, 10-13.
103. Fluiter, K., Frieden, M., Vreijling, J., Rosenbohm, C., De Wissel, M. B., Christensen, S. M., Koch, T., Orum, H., and Baas, F. (2005) On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-ras antisense oligonucleotide. Chembiochem 6, 1-6.
104. Fluiter, K., ten Asbroek, A. L. M. A., de Wissel, M. B., Jakobs, M. E., Wissenbach, M., Olsson, H., Olsen, O., Oerum, H., and Baas, F. (2003) In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides. Nucleic Acids Res. 31, 953-962.
105. Jepsen, J. S. and Wengel, J. (2004) LNA-antisense rivals siRNA for gene silencing. Curr. Opin. Drug Discov. Dev. 7, 188-194.
106. Swayze, E. E., Siwkowski, A. M., Wancewicz, E. V., Migawa, M. T., Wyrzykiewicz, T. K., Hung, G., Monia, B. P., and Bennett, C. F. (2007) Antisense oligonucleotides containing locked nucleic acid (LNA) improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res. 35, 687-700.
107. Ostergaard, M. E., Southwell, A. L., Kordasiewicz, H., Watt, A. T., Skotte, N. H., Doty, C. N., Vaid, K. et al. (2013) Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res. 41, 9634-9650.
108. Inoue, H., Hayase, Y., Iwai, S., and Ohtsuke, E. (1987) Sequence dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H. FEBS Lett. 215, 327-330.
109. Lima, W. F., Mohan, V., and Crooke, S. T. (1997) The influence of antisense oligonucleotide-induced RNA structure on Escherichia coli RNase H1 activity. J. Biol. Chem. 272, 18191-18199.
110. Lima, W. F. and Crooke, S. T. (1997) Cleavage of single strand RNA adjacent to RNA-DNA duplex regions by Escherichia coli RNase H1. J. Biol. Chem. 272, 27513-27516.
111. Wu, H., Lima, W. F., and Crooke, S. T. (1999) Properties of cloned and expressed human RNase H1. J. Biol. Chem. 274, 28270-28278.
112. Lamond, A. I. and Sproat, B. S. (1993) Antisense oligonucleotides made of 2'-O-alkylRNA: Their properties and applications in RNA biochemistry. FEBS Lett. 325, 123-127.
113. Yu, D., Iyer, R. P., Shaw, D. R., Lisziewicz, J., Li, Y., Jiang, Z., Roskey, A., and Agrawal, S. (1996) Hybrid oligonucleotides: Synthesis, biophysical properties, stability studies, and biological activity. Bioorg. Med. Chem. 4, 1685-1692.
114. Henry, S., Stecker, K., Brooks, D., Monteith, D., Conklin, B., and Bennett, C. F. (2000) Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J. Pharm. Exp. Ther. 292, 468-479.
115. Geary, R. S., Watanabe, T. A., Truong, L., Freier, S., Lesnik, E. A., Sioufi, N. B., Sasmor, H., Manoharan, M., and Levin, A. A. (2001) Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J. Pharmacol. Exp. Ther. 296, 890-897.
116. Geary, R. S., Khatsenko, O., Bunker, K., Crooke, R., Moore, M., Burckin, T., Truong, L., Sasmor, H., and Levin, A. A. (2001) Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats. J. Pharmacol. Exp. Ther.296, 898-904.
117. Yu, R. Z., Zhang, H., Geary, R. S., Graham, M., Masarjian, L., Lemonidis, K., Crooke, R., Dean, N. M., and Levin, A. A. (2001) Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice. J. Pharmacol. Exp. Ther. 296, 388-395.
118. Mendell, J. R., Rodino-Klapac, L. R., Sahenk, Z., Roush, K., Bird, L., Lowes, L. P., Alfano, L. et al. (2013) Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann. Neurol. 74, 637-647.
119. Goemans, N. M., Tulinius, M., van den Akker, J. T., Burm, B. E., Ekhart, P. F., Heuvelmans, N., Holling, T. et al. (2011) Systemic administration of PRO051 in Duchenne’s muscular dystrophy. N. Engl. J. Med. 364, 1513-1522.
120. Gryaznov, S. M. (1999) N3'→P5' phosphoramidates as potential therapeutic agents. Biochim. Biophys. Acta 1489, 131-147.
121. Faria, M., Spiller, D. G., Dubertret, C., Nelson, J. S., White, M. R. H., Scherman, D., Helene, C., and Giovannangeli, C. (2001) Phosphoramidate oligonucleotides as potent antisense molecules in cells and in vivo. Nat. Biotechnol. 19, 40-44.
122. Larsen, H. J., Bentin, T., and Nielsen, P. E. (1999) Antisense properties of peptide nucleic acid. Biochim. Biophys. Acta 1489, 159-166.
123. McMahon, B. M., Mays, D., Lipsky, J., Stewart, J. A., Fauq, A., and Richelson, E. (2002) Pharmacokinetics and tissue distribution of a peptide nucleic acid after intravenous administration. Antisense Nucleic Acid Drug Dev. 12, 65-73.
124. Maier, M. A., Esau, C. C., Siwkowski, A. M., Wancewicz, E. V., Albertshofer, K., Kingberger, G. A., Kabada, N. S. et al. (2006) Evaluation of basic amphipathic peptides for cellular delivery of antisense peptide nucleic acids. J. Med. Chem. 49, 2534-2542.
125. Albertshofer, K., Siwkowski, A., Wancewicz, E. V., Esau, C. C., Watanabe, T., Nishihara, K. C., Kinberger, G. A. et al. (2005) Structure-activity relationship study on simple cationic peptide motif for cellular delivery of antisense peptide nucleic acids. J. Med. Chem. 48, 6741-6749.
126. Summerton, J. and Weller, D. (1997) Morpholino antisense oligomers: Design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 7, 187-195.
127. Summerton, J. (1999) Morpholino antisense oligomers: The case for an RNase H-independent structural type. Biochim. Biophys. Acta 1489, 141-158.
128. Arora, V., Knapp, D. C., Smith, B. L., Stadtfield, M. L., Stein, D. A., Reddy, M. T., Weller, D. D., and Iversen, P. L. (2000) c-Myc antisense limits rat liver regeneration and indicates role for c-Myc in regulating cytochrome P-450 3A activity. J. Pharm. Exp. Ther. 292, 921-930.
129. Iversen, P. L., Arora, V., Acker, A. J., Mason, D. H., and Devi, G. R. (2003) Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a phase I safety study in humans. Clin. Cancer Res. 9, 2510-2519.
130. Stein, D. A., Huang, C. Y., Silengo, S., Amantana, A., Crumley, S., Blouch, R. E., Iversen, P. L., and Kinney, R. M. (2008) Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus. J. Antimicrob. Chemother.62, 555-565.
131. Arora, V., Knapp, D. C., Reddy, M. T., Weller, D. D., and Iversen, P. L. (2002) Bioavailability and efficacy of antisense morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats. J. Pharm. Sci. 91, 1009-1111.
132. Manoharan, M., Inamati, G. B., Lesnik, E. A., Sioufi, N. B., and Freier, S. M. (2002) Improving antisense oligonucleotide binding to human serum albumin: Dramatic effect of ibuprofen conjugation. Chembiochem 3, 1257-1260.
133. Manoharan, M. (2002) Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery, and mechanism of action. Antisense Nucleic Acid Drug Dev. 12, 103-128.
134. Cook, P. D. (2001) Medicinal chemistry of antisense oligonucleotides. in Antisense Drug Technology: Principles, Strategies, and Applications (Crooke, S. T. ed.), Marcel Dekker, New York. pp. 29-58.
135. Matteucci, M. (1996) Structural modifications toward improved antisense oligonucleotides. Perspectives Drug Dis. Des. 4, 1-16.
136. Braasch, D. A. and Corey, D. R. (2002) Novel antisense and peptide nucleic acid strategies for controlling gene expression. Biochemistry 41, 4503-4510.
137. Herdewijn, P. (2000) Heterocyclic modifications of oligonucleotides and antisense technology. Antisense Nucleic Acid Drug Dev. 10, 297-310.
138. Swayze, E. E. and Bhat, B. (2007) The medicinal chemistry of oligonucleotides. in Antisense Drug Technology: Principles, Strategies and Applications (Crooke, S. T. ed.), 2nd edn., Taylor & Francis, Boca Raton, FL. pp. 143-182.
139. Crooke, R. M., Graham, M. J., Cooke, M. E., and Crooke, S. T. (1995) In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. J. Pharmacol. Exp. Ther. 275, 462-473.
140. Krieg, A. M. (1993) Uptake and efficacy of phosphodiester and modified antisense oligonucleotides in primary cell cultures. Clin. Chem. 39, 710-712.
141. Stein, C. A., Tonkinson, J. L., Zhang, L.-M., Yakubov, L., Gervasoni, J., Taub, R., and Rotenberg, S. A. (1993) Dynamics of the internalization of phosphodiester oligodeoxynucleo-tides in HL60 cells. Biochemistry 32, 4855-4861.
142. Tonkinson, J. L. and Stein, C. A. (1994) Patterns of intracellular compartmentalization, trafficking and acidification of 5'-fluorescein labeled phosphodiester and phosphorothio-ate oligodeoxynucleotides in HL60 cells. Nucleic Acids Res. 22, 4268-4275.
143. Loke, S. L., Stein, C. A., Zhang, X. H., Mori, K., Nakanishi, M., Subasinghe, C., Cohen, J. S., and Neckers, L. M. (1989) Characterization of oligonucleotide transport into living cells. Proc. Natl. Acad. Sci. USA 86, 3474-3478.
144. Wu-Pong, S., Weiss, T. L., and Hunt, C. A. (1992) Antisense c-myc oligonucleotide cellular uptake. Pharm. Res. 9, 1010-1017.
145. Beltinger, C., Saragovi, H. U., Smith, R. M., LeSauteur, L., Shah, N., DeDionisio, L., Christensen, L., Raible, A., Jarett, L., and Gewirtz, A. M. (1995) Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxy-nucleotides. J. Clin. Invest. 95, 1814-1823.
146. Iversen, P. L., Zhu, S., Meyer, A., and Zon, G. (1992) Cellular uptake and subcellular distribution of phosphorothioate oligonucleotides into cultured cells. Antisense Res. Dev. 2, 211-222.
147. Koller, E., Vincent, T. M., Chappell, A., De, S., Manoharan, M., and Bennett, C. F. (2011) Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res. 39, 4795-4807.
148. Geary, R. S., Wancewicz, E. V., Matson, J. E., Pearce, M., Siwkowski, A., Swayze, E., and Bennett, F. (2009) Effect of dose and plasma concentration on liver uptake and pharmacological activity of a 2'-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN. Biochem. Pharmacol. 78, 284-291.
149. Ming, X., Carver, K., Fisher, M., Noel, R., Cintrat, J. C., Gillet, D., Barbier, J., Cao, C., Bauman, J., and Juliano, R. L. (2013) The small molecule Retro-1 enhances the pharmacological actions of antisense and splice switching oligonucleotides. Nucleic Acids Res. 41, 3673-3687.
150. Stein, C. A., Hansen, J. B., Lai, J., Wu, S., Voskresenskiy, A., Hog, A., Worm, J. et al. (2010) Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res. 38, e3.
151. Zhang, Y., Qu, Z., Kim, S., Shi, V., Liao, B., Kraft, P., Bandaru, R., Wu, Y., Greenberger, L. M., and Horak, I. D. (2011) Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection. Gene Ther. 18, 326-333.
152. Graham, M. J., Crooke, S. T., Monteith, D. K., Cooper, S. R., Lemonidis, K. M., Stecker, K. K., Martin, M. J., and Crooke, R. M. (1998) In vivo distribution and metabolism of a phos-phorothioate oligonucleotide within rat liver after intravenous administration. J. Pharmacol. Exp. Ther. 286, 447-458.
153. Butler, M., Stecker, K., and Bennett, C. F. (1997) Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab. Invest. 77, 379-388.
154. Yu, R. Z., Baker, B., Chappell, A., Geary, R. S., Cheung, E., and Levin, A. A. (2002) Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. Anal. Biochem. 304, 19-25.
155. Sewell, L. K., Geary, R. S., Baker, B. F., Glover, J. M., Mant, T. G. K., Yu, R. Z., Tami, J. A., and Dorr, F. A. (2002) Phase 1 trial of Isis 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J. Pharm. Exp. Ther. 303, 1334-1343.
156. Cossum, P. A., Sasmor, H., Dellinger, D., Truong, L., Cummins, L., Owens, S. R., Markham, P. M., Shea, J. P., and Crooke, S. (1993) Disposition of the 14C-labeled phosphoro-thioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exp. Ther. 267, 1181-1190.
157. Cossum, P. A., Truong, L., Owens, S. R., Markham, P. M., Shea, J. P., and Crooke, S. T. (1994) Pharmacokinetics of a 14C-labeled phosphorotioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J. Pharmacol. Exp. Ther. 269, 89-94.
158. Phillips, J. A., Craig, S. J., Bayley, D., Christian, R. A., Geary, R., and Nicklin, P. L. (1997) Pharmacokinetics, metabolism and elimination of a 20-mer phosphorothioate oligodeoxynu-cleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem. Pharmacol.54, 657-668.
159. Nicklin, P. L., Craig, S. J., and Phillips, J. A. (1998) Pharmacokinetic properties of phosphorothioates in ani-mals—Absorption, distribution, metabolism and elimination. in Antisense Research and Application, Springer-Verlag, Berlin, Germany. pp. 141-168.
160. Nicklin, P. L., Bayley, D., Giddings, J., Craig, S. J., Cummins, L. L., Hastewell, J. G., and Phillips, J. A. (1998) Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A): Comparison with other delivery routes. Pharm. Res. 15, 583-591.
161. Templin, M. V., Levin, A. A., Graham, M. J., Aberg, P. M., Axelsson, B. I., Butler, M., Geary, R. S., and Bennett, C. F. (1999) Pharmacokinetic and toxicity profile of a phosphoro-thioate oligodeoxynucleotide following inhalation delivery to lung in mice. Antisense Nucleic Acid Drug Dev. 10, 359-368.
162. Agrawal, S., Zhang, X., Lu, Z., Zhao, H., Tamburin, J. M., Yan, J., Cai, H. et al. (1995) Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem. Pharmacol. 50, 571-576.
163. Khatsenko, O., Morgan, R. A., Truong, L., York-Defalco, C., Sasmor, H., Conklin, B., and Geary, R. S. (2000) Absorption of antisense oligonucleotides in rat intestine: Effect of chemistry and length. Antisense Nucleic Acid Drug Dev. 10, 35-44.
164. Tillman, L. G., Geary, R. S., and Hardee, G. E. (2008) Oral delivery of antisense oligonucleotides in man. J. Pharm. Sci. 97, 225-236.
165. Geary, R. S., Leeds, J. M., Fitchett, J., Burckin, T., Truong, L., Spainhour, C., Creek, M., and Levin, A. A. (1997) Pharmacokinetics and metabolism in mice of a phosphoro-thioate oligonucleotide antisense inhibitor of C-RAF-1 kinase expression. Drug Metab. Dispos. 25, 1272-1281.
166. Geary, R. S., Yu, R. Z., Watanabe, T., Henry, S. P., Hardee, G. E., Chappell, A., Matson, J. E., Sasmor, H., Cummins, L., and Levin, A. A. (2003) Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: Comparison across species. Drug Metab. Dispos. 31, 1419-1428.
167. Levin, A. A., Geary, R. S., Leeds, J. M., Monteith, D. K., Yu, R., Templin, M. V., and Henry, S. P. (1998) The pharmacokinetics and toxicity of phosphorothioate oligonucleotides. in Biotechnology and Safety Assessment, Thomas, J.A., ed Taylor & Francis, Philadelphia, PA. pp. 1313-1317.
168. Levin, A. A., Yu, R. Z., and Geary, R. S. (2008) Basic principles of the pharmacokinetics of antisense oligonucleotide drugs. in Antisense Drug Technology: Principles, Strategies and Applications (Crooke, S. T. ed.), 2nd edn., Taylor & Francis, Boca Raton, FL. pp. 183-216.
169. Zhang, R., Lu, Z., Zhao, H., Zhang, X., Diasio, R. B., Habus, I., Jiang, Z., Iyer, R. P., Yu, D., and Agrawal, S. (1995) In vivo stability, disposition and metabolism of a “hybrid” oligonucleotide phosphorothioate in rats. Biochem. Pharmacol. 50, 545-556.
170. Crooke, S. T., Graham, M. J., Zuckerman, J. E., Brooks, D., Conklin, B. S., Cummins, L. L., Greig, M. J. et al. (1996) Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther. 277, 923-937.
171. Geary, R. S., Leeds, J. M., Henry, S. P., Monteith, D. K., and Levin, A. A. (1997) Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anti-Cancer Drug Des. 12, 383-393.
172. Glover, J. M., Leeds, J. M., Mant, T. G. K., Amin, D., Kisner, D. L., Zuckerman, J. E., Geary, R. S., Levin, A. A., and Shanahan, W. R., Jr. (1997) Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). J. Pharmacol. Exp. Ther 282, 1173-1180.
173. Yu, R. Z., Geary, R. S., Leeds, J. M., Watanabe, T., Moore, M., Fitchett, J., Matson, J., Burckin, T., Templin, M. V., and Levin, A. A. (2000) Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey. J. Pharm. Sci. 90, 182-193.
174. Geary, R. S., Yu, R. Z., Leeds, J. M., Watanabe, T. A., Henry, S. P., Levin, A. A., and Templin, M. V. (2001) Pharmacokinetic properties in animals. in Antisense Drug Technology: Principles, Strategies, and Applications (Crooke, S. T. ed.), Marcel Dekker, Inc., New York. pp. 119-154.
175. Watanabe, T. A., Geary, R. S., and Levin, A. A. (2006) Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleotides 16, 169-180.
176. Agrawal, S., Temsamani, J., and Tang, J. Y. (1991) Pharmacokinetics, biodistribution, and stability of oligode-oxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. USA 88, 7595-7599.
177. Bishop, M. R., Iversen, P. L., Bayever, E., Sharp, J. G., Greiner, T. C., Copple, B. L., Ruddon, R. et al. (1996) Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J. Clin. Oncol. 14, 1320-1326.
178. Graham, M., Crooke, S. T., Lemonidis, K. M., Gaus, H. J., Templin, M. V., and Crooke, R. M. (2001) Hepatic distribution of a phosphorothioate oligodeoxynucleotide within rodents following intravenous administration. Biochem. Pharmacol. 62, 297-306.
179. Plenat, F., Klein-Monhoven, N., Marie, B., Vignaud, J.-M., and Duprez, A. (1995) Cell and tissue distribution of synthetic oligonucleotides in healthy and tumor-bearing nude mice. Am. J. Pathol. 147, 124-135.
180. Benimetskaya, L., Tonkinson, J. L., Koziolkiewicz, M., Karwowski, B., Guga, P., Zeltser, R., Stec, W., and Stein, C. A. (1995) Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin in P-chirality independent. Nucleic Acids Res. 23, 4239-4245.
181. Graham, M. J., Lemonidis, K. M., Whipple, C. P., Subramaniam, S., Monia, B. P., Crooke, S. T., and Crooke, R. M. (2007) Antisense inhibition of proprotein convertase sub-tilisin kexin 9 reduces serum LDL-C in hyperlipidemic mice. J. Lipid Res. 48, 763-767.
182. Crooke, R. M., Graham, M. J., Lemonidis, K. M., Whipple, C. P., Koo, S., and Perera, R. J. (2005) An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyper-lipidemic mice without causing hepatic steatosis. J. Lipid Res. 46, 872-884.
183. Sloop, K. W., Showalter, A. D., Cox, A. L., Cao, J. X.-C., Siesky, A. M., Zhang, H. Y., Bodenmiller, D. M. et al. (2007) Decrease of hepatic glucose-6-phosphate transporter 1 ameliorates diabetes and avoids metabolic symptoms of glycogen storage disease. J. Biol. Chem. 282, 19113-19121.
184. Watts, L., Manchem, V., Leedom, T., Rivard, A., McKay, R. A., Bao, D., Neroladakis, T. et al. (2005) Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism. Diabetes 54, 1846-1853.
185. Yu, R. Z., Kim, T. W., Hong, A., Watanabe, T. A., Gaus, H. J., and Geary, R. (2007) Cross-species pharmacokinetic comparison from mouse to man of a second generation antisense oligonucleotide ISIS 301012, targeting human ApoB-100. Drug Metab. Dispos. 35, 460-468.
186. Geary, R. S., Yu, R. Z., Siwkowski, A., and Levin, A. A. (2008) Pharmacokinetic/pharmacodynamic properties of phosphorothioate 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides in animals and man. in Antisense Drug Technology: Principles, Strategies and Applications. (Crooke, S. T. ed.), Taylor & Francis, Boca Raton, FL. pp. 305-325.
187. Galbraith, W. M., Hobson, W. C., Giclas, P. C., Schechter, P. J., and Agrawal, S. (1994) Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev. 4, 201-206.
188. Henry, S. P., Bolte, H., Auletta, C., and Kornbrust, D. J. (1997) Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in cynomolgus monkeys. Toxicology 120, 145-155.
189. Henry, S. P., Grillone, L. R., Orr, J. L., Bruner, R. H., and Kornbrust, D. J. (1997) Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague -Dawley rats. Toxicology 116, 77-88.
190. Levin, A. A., Henry, S. P., Monteith, D., and Templin, M. V. (2001) Toxicity of antisense oligonucleotides. in Antisense Drug Technology: Principles, Strategies, and Applications (Crooke, S. T. ed.), Marcel Dekker, New York. pp. 201-267.
191. Henry, S. P., Kim, T.-W., Kramer-Strickland, K., Zanardi, T. A., Fey, R. A., and Levin, A. A. (2008) Toxicological Properties of 2'-O-methoxyethyl chimeric antisense inhibitors in animals and man. in Antisense Drug Technology: Principles, Strategies, and Applications (Crooke, S. T. ed.), 2nd edn., Taylor & Francis, Boca Raton, FL. pp. 327-363.
192. Levin, A. A., Monteith, D. K., Leeds, J. M., Nicklin, P. L., Geary, R. S., Butler, M., Templin, M. V., and Henry, S. P. (1998) Toxicity of oligodeoxynucleotide therapeutic agents. in Antisense Research and Application (Crooke, S. T. ed.), Springer-Verlag, Berlin, Germany. pp. 169-216.
193. Henry, S. P., Giclas, P. C., Leeds, J., Pangburn, M., Auletta, C., Levin, A. A., and Kornbrust, D. J. (1997) Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: Potential mechanism of action. J. Pharmacol. Exp. Ther 281, 810-816.
194. Sheehan, J. P. and Phan, T. M. (2001) Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex by an allosteric mechanism. Biochemistry 40, 4980-4989.
195. Henry, S. P., Novotny, W., Leeds, J., Auletta, C., and Kornbrust, D. J. (1997) Inhibition of coagulation by a phos-phorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev. 7, 503-510.
196. Wallace, T. L., Bazemore, S. A., Kornbrust, D. J., and Cossum, P. A. (1996) Repeat-dose toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after bolus intravenous administration to cynomolgus monkeys. J. Pharmacol. Exp. Ther. 278.
197. Nicklin, P. L., Ambler, J., Mitchelson, A., Bayley, D., Phillips, J. A., Craig, S. J., and Monia, B. P. (1997) Preclinical profiling of modified oligonucleotides: Anticoagulation and pharmacokinetic properties. Nucleosides Nucleotides 16, 1145-1153.
198. Sheehan, J. P. and Lan, H.-C. (1998) Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. Blood 92, 1617-1625.
199. Cornish, K. G., Iversen, P., Smith, L., Arneson, M., and Bayever, E. (1993) Cardiovascular effects of a phosphorothioate oligonucleotide to p53 in the conscious rhesus monkey. Pharmacol. Commun. 3, 239-247.
200. Black, L. E., Degeorge, J. J., Cavagnaro, J. A., Jordan, A., and Ahn, C. H. (1993) Regulatory considerations for evaluating the pharmacology and toxicology of antisense drugs. Antisense Res. Dev. 3, 399-404.
201. Black, L. E., Degeorge, J. J., Cavagnaro, J. A., Jordan, A., and Ahn, C.-H. (1994) Regulatory considerations for evaluating the pharmacology and toxicology of antisense drugs: Updated recommendations for pharmacology and toxicology studies. Antisense Res. Dev. 3, 399-404.
202. Crooke, S. T. and Geary, R. S. (2013) Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. Br. J. Clin. Pharmacol. 76, 269-276.
203. Leeds, J. M., Henry, S. P., Truong, L., Zutshi, A., Levin, A. A., and Kornbrust, D. (1997) Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit. Drug Metab. Dispos. 25, 921-926.
204. Leeds, J. M. and Geary, R. S. (1998) Pharmacokinetic properties of phosphorothioate oligonucleotides in humans. in Antisense Research and Application, Crooke, S.T., ed, Springer-Verlag, Berlin, Germany. pp. 217-241.
205. Monteith, D. K., Henry, S. P., Howard, R. B., Flournoy, S., Levin, A. A., Bennett, C. F., and Crooke, S. T. (1997) Immune stimulation—A class effect of phosphorothioate oligodeoxynucleotides in rodents. Anti-Cancer Drug Des. 12, 421-432.
206. Sarmiento, U. M., Perez, J. R., Becker, J. M., and Narayanan, R. (1994) In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice. Antisense Res. Dev. 4, 99-107.
207. Bennett, C. F., Kornbrust, D., Henry, S., Stecker, K., Howard, R., Cooper, S., Dutson, S., Hall, W., and Jacoby, H. I. (1997) An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. J. Pharmacol. Exp. Ther. 280, 988-1000.
208. Branda, R. F., Moore, A. L., Mathews, L., McCormack, J. J., and Zon, G. (1993) Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1. Biochem. Pharmacol. 45, 2037-2043.
209. Krieg, A. M., Yi, A.-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., and Klinman, D. M. (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546-549.
210. Kuramoto, E., Yano, O., Kimura, Y., Baba, M., Makino, T., Yamamoto, S., Yamamoto, T., Kataoka, T., and Tokunaga, T. (1992) Oligonucleotide sequences required for natural killer cell activation. Jpn. J. Cancer Res. 83, 1128-1131.
211. Rankin, R., Pontarollo, R., Ioannou, X., Krieg, A. M., Hecker, R., Babiuk, L. A., and vanDrunen Littel-va den Hurk, S. (2001) CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev. 11, 333-340.
212. Oberbauer, R., Schreiner, G. F., and Meyer, T. W. (1995) Renal uptake of an 18-mer phosphorothioate oligonucleotide. Kidney Int. 48, 1226-1232.
213. 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol. Pharmacol. 45, 932-943.
214. Monteith, D. K., Horner, M. J., Gilett, N. A., Butler, M., Geary, R. S., Burckin, T., Ushiro-Watanabe, T., and Levin, A. A. (1999) Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeys. Toxicol. Pathol. 27, 307-317.
215. Krieg, A. M. and Stein, C. A. (1995) Phosphorothioate oli-godeoxynucleotides: Antisense or anti-protein? [editorial]. Antisense Res. Dev. 5, 241.
216. Boggs, R. T., McGraw, K., Condon, T., Flournoy, S., Villiet, P., Bennett, C. F., and Monia, B. P. (1997) Characterization and modulation of immune stimulation by modified oligonucleotides. Antisense Nucleic Acid Drug Dev. 7, 461-471.
217. Henry, S. P., Zuckerman, J. E., Rojko, J., Hall, W. C., Harman, R. J., Kitchen, D., and Crooke, S. T. (1997) Toxicological properties of several novel oligonucleotide analogs in mice. Anti-Cancer Drug Des. 12, 1-14.
218. Zhao, Q., Temsamani, J., Iadarola, P. L., Jiang, Z., and Agrawal, S. (1995) Effect of different chemically modified oligodeoxynucleo-tides on immune stimulation. Biochem. Pharmacol. 51, 173-182.
219. Senn, J. J., Burel, S., and Henry, S. P. (2005) Non-CpG-containing antisense 2'-methoxyethyl oligonucleotides activate a proinflammatory response independent of toll-like receptor 9 or myeloid differentiation factor 88. J. Pharmacol. Exp. Ther 314, 972-979.
220. Azad, R. F., Driver, V. B., Tanaka, K., Crooke, R. M., and Anderson, K. P. (1993) Antiviral activity of a phosphorothio-ate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrobial Agents Chemother 37, 1945-1954.
221. Azad, R. F., Brown-Driver, V., Buckheit, Robert W. Jr.., and Anderson, K. P. (1995) Antiviral activity of a phosphorothio-ate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs. Antiviral Res. 28, 101-111.
222. Anderson, K. P., Fox, M. C., Brown-Driver, V., Martin, M. J., and Azad, R. F. (1996) Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA. Antimicrobial Agents Chemother. 40, 2004-2011.
223. Detrick, B., Nagineni, C. N., Grillone, L. R., Anderson, K. P., Henry, S. P., and Hooks, J. J. (2001) Inhibition of human cytomegalovirus replication in a human retinal epithelial cell model by antisense oligonucleotides. Invest. Ophthalmol. Vis. Sci. 42, 163-169.
224. Geary, R. S., Henry, S. P., and Grillone, L. R. (2002) Fomivirsen: Clinical pharmacology and potential drug interactions. Clin. Pharmacokinet. 41, 255-260.
225. Vitravene Study Group. (2002) Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS. Am. J. Ophthalmol. 133, 475-483.
226. Vitravene Study Group. (2002) Safety of intravitreous fomi-virsen for treatment of cytomegalovirus retinitis in patients with AIDS. Am. J. Ophthalmol. 133, 484-498.
227. Janssen, H. L., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A. J. et al. (2013) Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368, 1685-1694.
228. Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M., and Sarnow, P. (2005) Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA. Science 309, 1577-1581.
229. Gebert, L. F., Rebhan, M. A., Crivelli, S. E., Denzler, R., Stoffel, M., and Hall, J. (2014) Miravirsen (SPC3649) can inhibit the biogenesis of miR-122. Nucleic Acids Res. 42, 609-621.
230. Zellweger, T., Miyake, H., Cooper, S., Chi, K., Conklin, B. S., Monia, B. P., and Gleave, M. E. (2001) Antitumor activity of antisense oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry. J. Pharmacol. Exp. Ther. 298, 934-940.
231. Laskin, J. J., Nicholas, G., Lee, C., Gitlitz, B., Vincent, M., Cormier, Y., Stephenson, J. et al. (2012) Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. J. Thorac. Oncol. 7, 579-586.
232. Chi, K. N., Hotte, S. J., Yu, E. Y., Tu, D., Eigl, B. J., Tannock, I., Saad, F., North, S., Powers, J., Gleave, M. E., and Eisenhauer, E. A. (2010) Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28, 4247-4254.
233. Buettner, R., Mora, L. B., and Jove, R. (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. 8, 945-954.
234. Song, K., Turkson, J., Karras, J. G., Jove, R., and Haura, E. B. (2003) Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 22, 4150-4165.
235. Furqan, M., Akinleye, A., Mukhi, N., Mittal, V., Chen, Y., and Liu, D. (2013) STAT inhibitors for cancer therapy. J. Hematol. Oncol. 6, 90.
236. Alvarez, J. V., Febbo, P. G., Ramaswamy, S., Loda, M., Richardson, A., and Frank, D. A. (2005) Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res. 65, 5054-5062.
237. Rezvani, K. and Barrett, J. (2014) STAT3: The “Achilles” heel for AML? Blood 123, 1-2.
238. Niu, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S. et al. (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21, 2000-2008.
239. Mora, L. B., Buettner, R., Seigne, J., Diaz, J., Ahmad, N., Garcia, R., Bowman, T. et al. (2002) Constitutive activation of Stat3 in human prostate tumors and cell lines: Direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 62, 6659-6666.
240. Burel, S. A., Han, S. R., Lee, H. S., Norris, D. A., Lee, B. S., Machemer, T., Park, S. Y. et al. (2013) Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys. Nucleic Acid Ther. 23, 213-227.
241. Sapra, P., Wang, M., Bandaru, R., Zhao, H., Greenberger, L. M., and Horak, I. D. (2010) Down-modulation of sur-vivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotide. Nucleosides Nucleotides Nucleic Acids 29, 97-112.
242. Hansen, J. B., Fisker, N., Westergaard, M., Kjaerulff, L. S., Hansen, H. F., Thrue, C. A., Rosenbohm, C., Wissenbach, M., Orum, H., and Koch, T. (2008) SPC3042: A proapoptotic sur-vivin inhibitor. Mol. Cancer Ther. 7, 2736-2745.
243. Zhang, Y., Castaneda, S., Dumble, M., Wang, M., Mileski, M., Qu, Z., Kim, S. et al. (2011) Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer. Mol. Cancer Ther. 10, 2309-2319.
244. Lee, R. G., Fu, W., Graham, M. J., Mullick, A. E., Sipe, D., Gattis, D., Bell, T. A., Booten, S., and Crooke, R. M. (2013) Comparison of the pharmacological profiles of murine antisense oligonucleotides targeting apolipoprotein B and microsomal triglyceride transfer protein. J. Lipid Res. 54, 602-614.
245. Visser, M. E., Wagener, G., Baker, B. F., Geary, R. S., Donovan, J. M., Beuers, U. H., Nederveen, A. J. et al. (2012) Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: A randomized, double-blind, placebo-controlled trial. Eur. Heart J. 33, 1142-1149.
246. Visser, M. E., Akdim, F., Tribble, D. L., Nederveen, A. J., Kwoh, T. J., Kastelein, J. J., Trip, M. D., and Stroes, E. S. (2010) Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J. Lipid Res. 51, 1057-1062.
247. Akdim, F., Stroes, E. S., Sijbrands, E. J., Tribble, D. L., Trip, M. D., Jukema, J. W., Flaim, J. D. et al. (2010) Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J. Am. Coll. Cardiol. 55, 1611-1618.
248. Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M. J., Cromwell, W. C., Lachmann, R. H. et al. (2010) Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebo-controlled trial. Lancet 375, 998-1006.
249. McGowan, M. P., Tardif, J. C., Ceska, R., Burgess, L. J., Soran, H., Gouni-Berthold, I., Wagener, G., and Chasan-Taber, S. (2012) Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One 7, e49006.
250. Stein, E. A., Dufour, R., Gagne, C., Gaudet, D., East, C., Donovan, J. M., Chin W., Tribble, D. L., and McGowan, M. (2012) Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: Results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 126, 2283-2292.
251. Thomas, G. S., Cromwell, W. C., Ali, S., Chin W., Flaim, J. D., and Davidson, M. (2013) Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: A randomized, double-blind, placebo-controlled trial. J. Am. Coll. Cardiol. 62, 2178-2184.
252. Crosby, J. R., Marzec, U., Revenko, A. S., Zhao, C., Gao, D., Matafonov, A., Gailani, D. et al. (2013) Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. Arterioscler. Thromb. Vasc. Biol. 33, 1670-1678.
253. Merki, E., Graham, M., Taleb, A., Leibundgut, G., Yang, X., Miller, E. R., Fu, W. et al. (2011) Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J. Am. Coll. Cardiol. 57, 1611-1621.
254. Kjems, L. L., Bhanot, S., Bradley, J. D., Monia, B., Kwoh, J., and Wedel, M. K. (2005) Increased insulin sensitivity in humans by protein tyrosine phosphatase 1B (PTP-1B) inhibition-evaluation of ISIS 113715, an antisense inhibitor of PTP-1B. Diabetes 54, A530.
255. Meng, T.-C., Buckley, D. A., Galic, S., Tiganis, T., and Tonks, N. K. (2004) Regulation of insulin signaling through reversible oxidation of the protein-tyrosine phosphatases TC45 and PTP1B. J. Biol. Chem. 279, 37716-37725.
256. Zinker, B. A., Rondinone, C. M., Trevillyan, J. M., Gum, R. J., Clampit, J. E., Waring, J. F., Xie, N. et al. (2002) PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc. Natl. Acad. Sci. USA99, 11357-11362.
257. Swarbrick, M. M., Havel, P. J., Levin, A. A., Bremer, A. A., Stanhope, K. L., Butler, M., Booten, S. L. et al. (2009) Inhibition of protein tyrosine phosphatase-1B with antisense oligonucleotides improves insulin sensitivity and increases adiponectin concentrations in monkeys. Endocrinology 150, 1670-1679.
258. Liang, Y., Osborne, M. C., Monia, B. P., Bhanot, S., Watts, L. M., She, P., DeCarlo, S. O., Chen, X., and Demarest, K. (2005) Antisense oligonucleotides targeted against glucocorticoid receptor reduce hepatic glucose production and ameliorate hyperglycemia in diabetic mice. Metabolism 54, 848-855.
259. Sloop, K. W., Cao, J. X., Siesky, A. M., Zhang, H. Y., Bodenmiller, D. M., Cox, A. L., Jacobs, S. J. et al. (2004) Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J. Clin. Invest. 113, 1571-1581.
260. Liang, Y., Osborne, M. C., Monia, B. P., Bhanot, S., Gaarde, W. A., Reed, J. C., She, P., Jetton, T. L., and Demarest, K. T. (2004) Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes 53, 410-417.
261. Yu, R. Z., Geary, R. S., Monteith, D. K., Matson, J. E., Truong, L., Fitchett, J., and Levin, A. A. (2004) Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys. J. Pharm. Sci. 93, 48-59.
262. Smith, R. A., Miller, T. M., Yamanaka, K., Monia, B. P., Condon, T. P., Hung, G., Lobsiger, C. S. et al. (2006) Antisense oligonucleotide therapy for neurodegenerative disease. J. Clin. Invest. 116, 2290-2296.
263. Benson, M. D., Kluve-Beckerman, B., Zeldenrust, S. R., Siesky, A., Bodenmiller, D. M., Showalter, A. D., and Sloop, K. W. (2006) Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 33, 609-618.
264. Hammarstrom, P., Wiseman, R. L., Powers, E. T., and Kelly, J. W. (2003) Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 299, 713-716.
265. Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J. et al. (2013) Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 369, 819-829.
266. Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M. A., Bennett, C. F., and Krainer, A. R. (2010) Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 24, 1634-1644.
267. Passini, M. A., Bu, J., Richards, A. M., Kinnecom, C., Sardi, S. P., Stanek, L. M., Hua, Y. et al. (2011) Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci. Transl. Med. 3, 72ra18.
268. Miller, T. M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S. H., Andres, P. L. et al. (2013) An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: A phase 1, randomised, first-in-man study. Lancet Neurol. 12, 435-442.
269. Crawford, T. O. and Pardo, C. A. (1996) The neurobiology of childhood spinal muscular atrophy. Neurobiol. Dis. 3, 97-110.
270. Rigo, F., Hua, Y., Krainer, A. R., and Bennett, C. F. (2012) Antisense-based therapy for the treatment of spinal muscular atrophy. J. Cell Biol. 199, 21-25.
271. Southwell, A. L., Skotte, N. H., Bennett, C. F., and Hayden, M. R. (2012) Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. Trends Mol. Med. 18, 634-643.
272. Polymenidou, M., Lagier-Tourenne, C., Hutt, K. R., Bennett, C. F., Cleveland, D. W., and Yeo, G. W. (2012) Misregulated RNA processing in amyotrophic lateral sclerosis. Brain Res. 1462, 3-15.